In research, tirzepatide and semaglutide are both associated with an increased risk of gastrointestinal side effects, with tirzepatide causing more frequent disturbances (28)
Federal law generally bars compounders from making copies of FDA-approved drugs, but sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act allow compounding under certain circumstances, including during shortages
The relationship between serum lipid levels and diabetic nephropathy in patients with primary diabetes
Proanthocyanidins also inhibit the enzyme cyclooxygenase (the same enzyme inhibited by aspirin and other non-steroidal medications)
Key warning signs requiring urgent evaluation include: Postmenopausal bleeding (any vaginal bleeding occurring more than 12 months after the last menstrual period) Bleeding accompanied by fever, unusual vaginal discharge, or pelvic pain suggesting infection Bleeding associated with pregnancy or suspected pregnancy Recurrent spotting that persists for more than two to three menstrual cycles Patients taking tirzepatide who develop abnormal bleeding should undergo a comprehensive gynecological assessment, including detailed menstrual history, pelvic examination, and pregnancy testing for all reproductive-age women regardless of contraceptive use